Orit Freedman

4.3k total citations · 1 hit paper
40 papers, 2.3k citations indexed

About

Orit Freedman is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Orit Freedman has authored 40 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 16 papers in Cancer Research and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Orit Freedman's work include Breast Cancer Treatment Studies (16 papers), Cancer Treatment and Pharmacology (12 papers) and HER2/EGFR in Cancer Research (8 papers). Orit Freedman is often cited by papers focused on Breast Cancer Treatment Studies (16 papers), Cancer Treatment and Pharmacology (12 papers) and HER2/EGFR in Cancer Research (8 papers). Orit Freedman collaborates with scholars based in Canada, United Kingdom and United States. Orit Freedman's co-authors include Eitan Amir, Boštjan Šeruga, D. Gareth Evans, Olivier Trédan, Shin‐Cheh Chen, Martin Frenzel, Masakazu Toi, Matthew P. Goetz, Joohyuk Sohn and Susana Barriga and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Orit Freedman

39 papers receiving 2.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

2017 1.1k citations Matthew P. Goetz, Masakazu Toi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Orit Freedman Canada	18	1.5k	1.3k	718	344	286	40	2.3k
Ted Vandenberg Canada	19	1.4k 0.9×	585 0.5×	761 1.1×	279 0.8×	89 0.3×	39	2.0k
Katalin Boér Hungary	15	1.7k 1.1×	1.9k 1.5×	668 0.9×	178 0.5×	400 1.4×	54	2.6k
Elisabet Lidbrink Sweden	24	1.7k 1.1×	628 0.5×	832 1.2×	343 1.0×	69 0.2×	51	2.4k
D. Amoroso Italy	23	2.0k 1.3×	791 0.6×	925 1.3×	668 1.9×	85 0.3×	104	2.8k
Giorgio Cocconi Italy	25	1.4k 0.9×	769 0.6×	421 0.6×	223 0.6×	156 0.5×	85	2.2k
A. Farris Italy	23	949 0.6×	408 0.3×	599 0.8×	353 1.0×	103 0.4×	81	1.6k
John R. Goffin Canada	24	988 0.6×	833 0.7×	560 0.8×	423 1.2×	59 0.2×	72	2.3k
Yasuo Hozumi Japan	23	964 0.6×	522 0.4×	704 1.0×	549 1.6×	66 0.2×	84	1.9k
Francisco Sapunar United Kingdom	14	1.1k 0.7×	846 0.7×	522 0.7×	585 1.7×	74 0.3×	33	1.7k
Ruben G.W. Quek United States	20	1.8k 1.2×	916 0.7×	683 1.0×	767 2.2×	114 0.4×	80	3.0k

Countries citing papers authored by Orit Freedman

Since Specialization

Citations

This map shows the geographic impact of Orit Freedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Orit Freedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Orit Freedman more than expected).

Fields of papers citing papers by Orit Freedman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Orit Freedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Orit Freedman. The network helps show where Orit Freedman may publish in the future.

Co-authorship network of co-authors of Orit Freedman

This figure shows the co-authorship network connecting the top 25 collaborators of Orit Freedman. A scholar is included among the top collaborators of Orit Freedman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Orit Freedman. Orit Freedman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McGee, Sharon F., Mark Clemons, Gregory R. Pond, et al.. (2024). A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer. Current Oncology. 31(8). 4531–4545. 2 indexed citations

Clemons, Mark, George Dranitsaris, Sandeep Sehdev, et al.. (2020). A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting. The Breast. 54. 278–285. 21 indexed citations

Freedman, Orit, et al.. (2018). Evaluation of a comprehensive geriatric assessment tool in geriatric cancer patients undergoing adjuvant chemotherapy: a pilot study. Supportive Care in Cancer. 27(5). 1871–1877. 3 indexed citations

Goetz, Matthew P., Masakazu Toi, Mario Campone, et al.. (2017). MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology. 35(32). 3638–3646. 1125 indexed citations breakdown →

Leo, Angelo Di, Masakazu Toi, Mario Campone, et al.. (2017). MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer. Annals of Oncology. 28. v609–v609. 13 indexed citations

Gandhi, Sonal, Glenn G. Fletcher, Andrea Eisen, et al.. (2015). Adjuvant Chemotherapy for Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. Current Oncology. 22(11). 82–94. 28 indexed citations

Freedman, Orit, Glenn G. Fletcher, Sonal Gandhi, et al.. (2015). Adjuvant Endocrine Therapy for Early Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. Current Oncology. 22(11). 95–113. 30 indexed citations

Mates, Mihaela, Glenn G. Fletcher, Orit Freedman, et al.. (2015). Systemic Targeted Therapy for her2-Positive Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. Current Oncology. 22(11). 114–122. 28 indexed citations

Ocaña, Alberto, Orit Freedman, Eitan Amir, Boštjan Šeruga, & Atanasio Pandiella. (2013). Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. Cancer and Metastasis Reviews. 33(1). 295–307. 6 indexed citations

10.

Amir, Eitan, Orit Freedman, Lindsay Carlsson, et al.. (2012). Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast Cancer. American Journal of Clinical Oncology. 36(5). 436–442. 31 indexed citations

11.

Amir, Eitan, Mark Clemons, Colin A. Purdie, et al.. (2011). Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treatment Reviews. 38(6). 708–714. 139 indexed citations

12.

Hilton, John, Lisa Vandermeer, Sean Hopkins, et al.. (2011). A multicenter study assessing 12-weekly intravenous bisphosphonate therapy in women with low-risk bone metastases from breast cancer: The TRIUMPH trial.. Journal of Clinical Oncology. 29(15_suppl). TPS242–TPS242. 1 indexed citations

13.

Amir, Eitan, Alberto Ocaña, Boštjan Šeruga, Orit Freedman, & Mark Clemons. (2010). Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treatment Reviews. 36(5). 410–415. 28 indexed citations

14.

Freedman, Orit, Eitan Amir, & Mark Clemons. (2009). Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?. Critical Reviews in Oncology/Hematology. 72(1). 56–64. 2 indexed citations

15.

Freedman, Orit, Eitan Amir, George Dranitsaris, et al.. (2009). Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. Breast Cancer Research and Treatment. 118(2). 377–383. 6 indexed citations

16.

Molckovsky, Andrea, Barbara Fitzgerald, Orit Freedman, Ruth Heisey, & Mark Clemons. (2009). Approach to inflammatory breast cancer.. PubMed. 55(1). 25–31. 17 indexed citations

17.

Freedman, Orit, Eitan Amir, Wedad Hanna, et al.. (2009). A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. Breast Cancer Research and Treatment. 119(1). 155–161. 12 indexed citations

18.

Bédard, Philippe L., Orit Freedman, Anthony Howell, & Mark Clemons. (2007). Overcoming endocrine resistance in breast cancer—are signal transduction inhibitors the answer?. Breast Cancer Research and Treatment. 108(3). 307–317. 35 indexed citations

19.

Freedman, Orit, Sunil Verma, & Mark Clemons. (2006). Pre-menopausal breast cancer and aromatase inhibitors: treating a new generation of women. Breast Cancer Research and Treatment. 99(3). 241–247. 14 indexed citations

20.

Salmon, Kirsty, Orit Freedman, Bruce W. Ritchings, & Michael S. DuBow. (2000). Characterization of the Lysogenic Repressor (c) Gene of the Pseudomonas aeruginosa Transposable Bacteriophage D3112. Virology. 272(1). 85–97. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact